Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

0.4600
+0.02235.09%
Post-market: 0.46000.00000.00%18:58 EDT
Volume:476.46K
Turnover:216.39K
Market Cap:135.81M
PE:-0.35
High:0.4747
Open:0.4600
Low:0.4300
Close:0.4377
Loading ...

Lyell Immunopharma price target lowered to 60c from $1 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Zacks
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
24 Dec 2024

Lyell Immunopharma presents positive data from Phase 1-2 IMPT-314 study

TIPRANKS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA

Reuters
·
10 Dec 2024

Lyell Presents Positive Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 Ash Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA

THOMSON REUTERS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Files Prospectus Related To Resale From Time To Time By Selling Stockholders Of Up To 37.5 Million Shares Of Common Stock

Reuters
·
30 Nov 2024

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know

Zacks
·
15 Nov 2024

Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges

TIPRANKS
·
12 Nov 2024

Lyell Immunopharma Reports Q3 2024 Financial Results

TIPRANKS
·
08 Nov 2024

Lyell Immunopharma Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $34.00K Up From $25.00K YoY

Benzinga
·
08 Nov 2024

Lyell Immunopharma: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

Lyell Immunopharma Q3 Revenue USD 34 Thousand

THOMSON REUTERS
·
08 Nov 2024

Lyell Immunopharma : Our Strong Cash Position Enables US to Advance Our Pipeline Through Important Clinical Milestones and Fund Operations Into 2027

THOMSON REUTERS
·
08 Nov 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

GlobeNewswire
·
08 Nov 2024

Lyell Announces Presentation of Initial Clinical Data From the Phase 1-2 Clinical Trial of Impt-314 for the Treatment of B-Cell Lymphoma at the 2024 American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
05 Nov 2024

Buy/Sell: Wall Street's Top 10 Stock Calls This Week

The Fly
·
03 Nov 2024